EGFR and adenocarcinoma: The efficacy of the EGFR-TKIs is largely unknown for cancers harboring uncommon or rare EGFR mutations.<h4>Case presentation</h4>A 69-year-old woman was diagnosed with adenocarcinoma cT4N2M1c, stage IVB.